Treatment of endometrial thickness with metformin and progesterone

Comparing treatment of endometrial hyperplasia with metformin plus progesterone and progesterone alone

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20230128057254N1

Enrollment

100

Registered

2023-10-30

Start date

2023-05-05

Completion date

Unknown

Last updated

2023-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometrial hyperplasia. Endometrial hyperplasia

Interventions

Intervention 1: Intervention group: patients with endometrial hyperplasia without atypia will receive metformin 500 mg twice daily for 3 months period added to medroxyprogesterone acetate 10 mg/day f

Eligibility

Sex/Gender

Female

Age

18 Years to 55 Years

Inclusion criteria

Inclusion criteria: Endometrial hyperplasia confirmed by endometrial biopsy Absence of liver and kidney disease Consent to participate in the study

Exclusion criteria

Exclusion criteria: Use of metformin within the last 6 months Impaired liver and kidney tests Diabetics treated with insulin Postmenopausal women Intolerance to metformin side effects

Design outcomes

Primary

Measure	Time frame
Endometrial hyperplasia. Timepoint: 3 months and 6 months after intervention initiation. Method of measurement: Endometrial curettage.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactRahele Jabbari

Qazvin University of Medical Sciences

Dr.rahelleh7060@yahoo.com+98 912 941 2976

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Aug 22, 2026